|
289 Companies |
|
443 Products |
|
443 Products |
|
177 Mechanisms of Action |
|
23 Trials |
|
5319 News |
|
| «12...89101112131415161718...109110» |
- || Xalkori (crizotinib) / Pfizer
Trial primary completion date, Combination therapy: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Feb 14, 2017
P1, N=65, Recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Apr 2017 --> Oct 2018
- Kymriah (tisagenlecleucel-T) / Novartis
Enrollment change, Trial withdrawal, Trial primary completion date: Study of Efficacy and Safety of CTL019 in Adult ALL Patients (clinicaltrials.gov) - Feb 14, 2017
P2, N=0, Withdrawn, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Apr 2017 --> Oct 2018 N=67 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2017 --> Jan 2017
- zoledronic acid / Generic mfg.
Trial completion, Enrollment change: Zometa Study in Pediatric Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 14, 2017
P=N/A, N=95, Completed, Sponsor: Children's Cancer Hospital Egypt 57357
N=67 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2017 --> Jan 2017 Suspended --> Completed | N=120 --> 95
- |||| mercaptopurine / Generic mfg., thioguanine / Generic mfg.
Trial primary completion date: Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 12, 2017
P3, N=1970, Completed, Sponsor: Children's Oncology Group
Suspended --> Completed | N=120 --> 95 Trial primary completion date: Feb 2000 --> Mar 2007
- Trial completion, Enrollment change, FDG PET: Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET) (clinicaltrials.gov) - Feb 12, 2017
P=N/A, N=8, Completed, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Feb 2000 --> Mar 2007 Recruiting --> Completed | N=36 --> 8
- Trial completion, Metastases: T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer (clinicaltrials.gov) - Feb 12, 2017
P1, N=39, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Completed | N=36 --> 8 Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date: Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies (clinicaltrials.gov) - Feb 12, 2017
P1, N=23, Completed, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed Recruiting --> Completed | N=15 --> 23 | Trial primary completion date: Jun 2010 --> Apr 2011
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion, Enrollment change: Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL (clinicaltrials.gov) - Feb 12, 2017
P2, N=15, Completed, Sponsor: Weill Medical College of Cornell University
Recruiting --> Completed | N=15 --> 23 | Trial primary completion date: Jun 2010 --> Apr 2011 Active, not recruiting --> Completed | N=30 --> 15
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment change, Trial withdrawal: Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas (clinicaltrials.gov) - Feb 11, 2017
P2, N=0, Withdrawn, Sponsor: Massachusetts Eye and Ear Infirmary
Active, not recruiting --> Completed | N=30 --> 15 N=15 --> 0 | Completed --> Withdrawn
- Veltucyn (veltuzumab) / Gilead, Epratucyn (epratuzumab) / Gilead
Enrollment closed, Enrollment change: Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma (clinicaltrials.gov) - Feb 11, 2017
P1/2, N=5, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
N=15 --> 0 | Completed --> Withdrawn Recruiting --> Active, not recruiting | N=20 --> 5
- | Trial completion: AMG 319 Lymphoid Malignancy FIH (clinicaltrials.gov) - Feb 11, 2017
P1, N=28, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=20 --> 5 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, plerixafor / Generic mfg.
Trial completion: Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors (clinicaltrials.gov) - Feb 11, 2017
P2, N=48, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- dasatinib / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Feb 11, 2017
P2, N=2, Completed, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed Recruiting --> Completed | N=21 --> 2 | Trial primary completion date: Dec 2012 --> Dec 2010
- OXS-1550 / GT Biopharma
Trial completion, Trial initiation date: DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma (clinicaltrials.gov) - Feb 11, 2017
P1, N=25, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Completed | N=21 --> 2 | Trial primary completion date: Dec 2012 --> Dec 2010 Active, not recruiting --> Completed | Initiation date: Apr 2009 --> Dec 2013
- | mercaptopurine / Generic mfg., thioguanine / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 9, 2017
P3, N=1970, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Initiation date: Apr 2009 --> Dec 2013 No longer recruiting --> Completed
- Trial primary completion date: Proton Beam Re-Irradiation in Thoracic Cancers (clinicaltrials.gov) - Feb 9, 2017
P=N/A, N=20, Recruiting, Sponsor: University of Washington
No longer recruiting --> Completed Trial primary completion date: Jul 2017 --> Feb 2018
- | telaglenastat (CB-839) / Calithera
Trial completion, Enrollment change, Trial primary completion date: Study of the Glutaminase Inhibitor CB-839 in Leukemia (clinicaltrials.gov) - Feb 9, 2017
P1, N=43, Completed, Sponsor: Calithera Biosciences, Inc
Trial primary completion date: Jul 2017 --> Feb 2018 Recruiting --> Completed | N=100 --> 43 | Trial primary completion date: Jun 2016 --> Oct 2016
- Arzerra (ofatumumab) / Novartis, Genmab, dinaciclib (MK-7965) / Merck (MSD)
Trial primary completion date: Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov) - Feb 8, 2017
P1b/2, N=37, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=100 --> 43 | Trial primary completion date: Jun 2016 --> Oct 2016 Trial primary completion date: Jun 2012 --> Mar 2015
- || Qinprezo (vosaroxin) / Denovo
Phase classification, Enrollment change, Trial primary completion date, Metastases: Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies (clinicaltrials.gov) - Feb 8, 2017
P1b, N=75, Completed, Sponsor: Sunesis Pharmaceuticals
Trial primary completion date: Jun 2012 --> Mar 2015 Phase classification: P1 --> P1b | N=30 --> 75 | Trial primary completion date: Aug 2008 --> Dec 2008
- Trial completion, Trial primary completion date: The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients (clinicaltrials.gov) - Feb 8, 2017
P=N/A, N=149, Completed, Sponsor: Indiana University
Phase classification: P1 --> P1b | N=30 --> 75 | Trial primary completion date: Aug 2008 --> Dec 2008 Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jan 2017
- | Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Feb 8, 2017
P2, N=28, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jan 2017 Active, not recruiting --> Completed | Trial primary completion date: Nov 2013 --> Jul 2006
- Graspa (eryaspase) / PHAXIAM Therap
Trial primary completion date, Combination therapy: L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL (clinicaltrials.gov) - Feb 8, 2017
P1, N=12, Recruiting, Sponsor: ERYtech Pharma
Active, not recruiting --> Completed | Trial primary completion date: Nov 2013 --> Jul 2006 Trial primary completion date: Dec 2016 --> Sep 2017
- Enrollment change, Adherence: Promoting Adherence to Lymphedema Self-care (clinicaltrials.gov) - Feb 7, 2017
P=N/A, N=160, Completed, Sponsor: Vanderbilt University
Trial primary completion date: Dec 2016 --> Sep 2017 N=110 --> 160
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Enrollment change, Trial primary completion date: Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Feb 7, 2017
P1/2, N=14, Completed, Sponsor: Weill Medical College of Cornell University
N=110 --> 160 Recruiting --> Completed | N=46 --> 14 | Trial primary completion date: Jan 2013 --> Sep 2013
- bazlitoran (IMO-8400) / Idera
Trial completion, Trial primary completion date: Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation (clinicaltrials.gov) - Feb 7, 2017
P1/2, N=6, Completed, Sponsor: Idera Pharmaceuticals, Inc.
Recruiting --> Completed | N=46 --> 14 | Trial primary completion date: Jan 2013 --> Sep 2013 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Dec 2016
- | Promune (agatolimod) / Pfizer
Trial completion: CPG 7909 in Patients With Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Feb 6, 2017
P1/2, N=42, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Dec 2016 Recruiting --> Completed
- | Promune (agatolimod) / Pfizer
Trial completion: A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated (clinicaltrials.gov) - Feb 6, 2017
P1, N=41, Completed, Sponsor: University of Iowa
Recruiting --> Completed Active, not recruiting --> Completed
- Neulasta (pegfilgrastim) / Roche, Rituxan (rituximab) / Roche
Trial completion, Combination therapy: Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma (clinicaltrials.gov) - Feb 6, 2017
P2, N=20, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Feb 3, 2017
P2, N=119, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Aug 2017 --> Aug 2018
- Trial termination: Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 3, 2017
P=N/A, N=30, Terminated, Sponsor: Rutgers, The State University of New Jersey
Trial primary completion date: Aug 2017 --> Aug 2018 Active, not recruiting --> Terminated; slow accrual
- Adcetris (brentuximab vedotin) / Seagen, Takeda
Trial completion, Trial primary completion date: Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma (clinicaltrials.gov) - Feb 3, 2017
P2, N=57, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Terminated; slow accrual Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> Feb 2017
- Trial termination: Proton Radiation for Lymphoma Involving Mediastinum (clinicaltrials.gov) - Feb 3, 2017
P=N/A, N=12, Terminated, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> Feb 2017 Active, not recruiting --> Terminated; Slow accrual rates/ lack of funding
- temozolomide / Generic mfg.
Phase classification: DRBEAT: The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma (clinicaltrials.gov) - Feb 2, 2017
P2a, N=20, Recruiting, Sponsor: Cedars-Sinai Medical Center
Active, not recruiting --> Terminated; Slow accrual rates/ lack of funding Phase classification: P2 --> P2a
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial initiation date, Trial termination, Trial primary completion date: Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies (clinicaltrials.gov) - Feb 1, 2017
P2, N=9, Terminated, Sponsor: Sherif S. Farag
Phase classification: P2 --> P2a Initiation date: Dec 2007 --> Aug 2007 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2016 --> May 2016; Slow accrual
- Trial primary completion date: Airway Vascular Lesions (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=75, Active, not recruiting, Sponsor: University of Arkansas
Initiation date: Dec 2007 --> Aug 2007 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2016 --> May 2016; Slow accrual Trial primary completion date: Dec 2016 --> Dec 2017
- Phase classification: Bioelectrical Impedance for Self-monitoring of Lymphedema (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=72, Completed, Sponsor: Vanderbilt University
Trial primary completion date: Dec 2016 --> Dec 2017 Phase classification: P4 --> P=N/A
- ||||||| Arzerra (ofatumumab) / Novartis, Genmab
Trial completion, Trial primary completion date: HOMER: Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy (clinicaltrials.gov) - Jan 30, 2017
P3, N=516, Completed, Sponsor: Novartis Pharmaceuticals
Phase classification: P4 --> P=N/A Active, not recruiting --> Completed | Trial primary completion date: Sep 2020 --> Dec 2016
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion, Enrollment change, Combination therapy: Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jan 30, 2017
P1/2, N=17, Completed, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed | Trial primary completion date: Sep 2020 --> Dec 2016 Recruiting --> Completed | N=32 --> 17
- Trial completion, Adherence: Promoting Adherence to Lymphedema Self-care (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=110, Completed, Sponsor: Vanderbilt University
Recruiting --> Completed | N=32 --> 17 Active, not recruiting --> Completed
- Signifor LAR (pasireotide long acting release) / Recordati
Trial completion, Trial primary completion date: Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer (clinicaltrials.gov) - Jan 26, 2017
P2, N=91, Completed, Sponsor: Alliance Pour La Recherche en Cancerologie
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Apr 2012 --> Oct 2012
- | lenalidomide / Generic mfg., ibrutinib / Generic mfg.
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: MCL-004: Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment (clinicaltrials.gov) - Jan 26, 2017
P=N/A, N=30, Completed, Sponsor: Celgene
Recruiting --> Completed | Trial primary completion date: Apr 2012 --> Oct 2012 Recruiting --> Completed | N=45 --> 30 | Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Jun 2016 --> Sep 2016
- Rituxan (rituximab) / Roche
Trial primary completion date: IELSG32: Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (clinicaltrials.gov) - Jan 24, 2017
P2, N=126, Active, not recruiting, Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Recruiting --> Completed | N=45 --> 30 | Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Jun 2016 --> Sep 2016 Trial primary completion date: Dec 2016 --> Mar 2017
- || Trial primary completion date: PRECIS: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients (clinicaltrials.gov) - Jan 24, 2017
P2, N=140, Active, not recruiting, Sponsor: Institut Curie
Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Feb 2017 --> Aug 2017
- ||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment closed, Enrollment change, Combination therapy: Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jan 24, 2017
P2, N=87, Active, not recruiting, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: Feb 2017 --> Aug 2017 Recruiting --> Active, not recruiting | N=125 --> 87
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Enrollment closed: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=12, Active, not recruiting, Sponsor: Baylor College of Medicine
Recruiting --> Active, not recruiting | N=125 --> 87 Recruiting --> Active, not recruiting
- | Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion: Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Jan 24, 2017
P2, N=16, Completed, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Campath (alemtuzumab) / Sanofi
Trial completion, IO biomarker: CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas (clinicaltrials.gov) - Jan 23, 2017
P1, N=24, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Trial initiation date, Trial primary completion date: OPBG_359.11: Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT (clinicaltrials.gov) - Jan 23, 2017
P1/2, N=30, Completed, Sponsor: Mariella Enoc
Active, not recruiting --> Completed Recruiting --> Completed | Initiation date: Sep 2011 --> Jan 2012 | Trial primary completion date: Sep 2013 --> Sep 2016
- everolimus / Generic mfg., bendamustine / Generic mfg.
Trial primary completion date: Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) - Jan 23, 2017
P1, N=18, Recruiting, Sponsor: University of California, Davis
Recruiting --> Completed | Initiation date: Sep 2011 --> Jan 2012 | Trial primary completion date: Sep 2013 --> Sep 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- | Ontak (denileukin diftitox) / Eisai, TSD Japan
Trial completion: Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 18, 2017
P2, N=0, Completed, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Dec 2016 --> Dec 2017 No longer recruiting --> Completed